Tag: Bayer
Bayer granted priority review by US FDA for secondary stroke prevention...
Bayer has announced that the US Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) and granted priority review designation...
Asundexian found to reduce severity of secondary strokes
Bayer has announced late-breaking data from new analyses of the phase-three OCEANIC-STROKE study comparing asundexian versus placebo in combination with antiplatelet therapy. These analyses—presented...
Investigational Factor XIa inhibitor achieves reduction in secondary ischaemic stroke
The investigational anti-clotting medication asundexian (Bayer) has demonstrated a reduction in the risk of a second ischaemic stroke without raising bleeding-related concerns, according to preliminary...
ISC 2023 sees presentation of positive data on new stroke drugs...
New data pointing to the possible advantages held by several drug products in treating acute ischaemic stroke were delivered at the recent International Stroke...
